Anadol

Quick links to important sections

Anadol

Treatment option: Pain, Chronic Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anadol

Property Description
Active ingredient Tramadol Hydrochloride
Form Tablets, Capsules, Solution (Oral/Injectable)
Pharmacological class Opioid Analgesic, Synthetic Opioid
Common use Systemic relief of moderate to severe pain
Origin Synthetic Compound

Defining Anadol: Identity and Core Composition

Anadol is a pharmaceutical preparation recognized for its efficacy in providing relief for moderate to severe pain. The active ingredient is Tramadol Hydrochloride. This compound is classified as a synthetic opioid, meaning it is chemically manufactured rather than being a natural derivative of opium; Anadol is utilized as a single-agent product, relying on Tramadol Hydrochloride to deliver its systemic effects alongside necessary pharmaceutical excipients.

Pharmacological Classification and Dual Action

Anadol is categorized as an opioid analgesic and is classified as a centrally acting synthetic opioid, placing it within the domain of central nervous system (CNS) depressants. Its mechanism is that of a dual-acting analgesic because it engages in two complementary actions: acting on the mu-opioid receptors and modifying the reuptake of the neurotransmitters serotonin and norepinephrine. The benefit of this dual profile is its capacity for providing analgesia in situations where pain is persistent.

Available Forms and General Purpose

The general therapeutic purpose of Anadol is to offer systemic pain relief. To ensure suitability across various clinical needs, the drug is manufactured in several distinct dosage forms, including oral tablets (immediate-release and extended-release), capsules, and a sterile injectable solution. The availability of both oral and parenteral forms demonstrates its positioning as a versatile treatment, allowing the route of administration to be tailored to the patient’s condition.

Regulatory References

  1. MedlinePlus Drug Information
  2. NIH Pharmacological Review

What side effects are possible with Anadol?

Possible Side Effects and Safety Information

Adverse reactions associated with Anadol (Tramadol Hydrochloride) are officially classified by frequency and by the affected System-Organ Class (SOC) as documented in regulatory sources.


Frequency-Classified Adverse Reactions

The most frequently observed effects, officially categorized as Very Common (ge 10% incidence), relate primarily to the Nervous and Gastrointestinal Systems. These include Nausea, Dizziness/Vertigo, Constipation, Headache, and Somnolence (drowsiness). Reactions classified as Common (1% to 10%) include vomiting, pruritus (itchiness), dry mouth, sweating, and confusion.

Rare events (0.01% to 0.1% incidence) include severe adverse reactions such as Respiratory Depression, Epileptiform Convulsions, and Anaphylaxis.


Serious Adverse Reactions and Safety Constraints

The official safety profile highlights the risk of several serious adverse reactions, which may occur even at recommended doses. These include Serotonin Syndrome, a potentially life-threatening condition, and the risk of Severe Hypotension and Seizures. The drug also carries a documented risk of Addiction, Abuse, and Misuse leading to overdose and death.

Safety constraints dictate that Anadol is contraindicated for use in children under 12 years of age and in adolescents under 18 years following certain surgical procedures. Prolonged maternal use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome.


Time- and Population-Related Safety Patterns

Safety documents specify that the risks of Respiratory Depression and Severe Hypotension are highest during the initiation of therapy or following a dose increase. Furthermore, physical dependence may develop with chronic use. Patients with severe hepatic or renal impairment may require specific regimen adjustments as advised in the official prescribing information.

Overdose and Emergency Response

Overdose Scope and Manifestations

Overdose of Anadol (Tramadol Hydrochloride) is documented to present with severe manifestations primarily affecting the central nervous system and respiratory system. The most serious consequence described in official regulatory information is life-threatening respiratory depression, which can progress to coma or death. Other documented overdose presentations include profound sedation, generalized seizures (convulsions), severe hypotension, and miosis (pinpoint pupils). The official profile also notes the potential for Serotonin Syndrome as a severe outcome. Dose-related factors note that high doses increase the risk of seizures.


Emergency Response and Specific Risks

Immediate emergency medical attention is required upon observing any signs of severe overdose, such as inability to wake up or slow, shallow breathing. The official labeling requires that management involves symptomatic and supportive treatment, maintaining a patent airway, and providing assisted ventilation. The opioid antagonist naloxone is the recommended reversal agent for respiratory depression, though its effect may be only partial and administration may increase the risk of seizures. Accidental ingestion by children is documented as a risk for fatal overdose. Furthermore, ultra-rapid metabolizers and elderly patients are specified in the labeling as populations with a heightened risk for life-threatening respiratory depression.

Therapeutic Uses of Anadol

Anadol is an over-the-counter medicine primarily used to help manage symptoms of common, temporary conditions. Its core therapeutic use is to provide temporary relief from mild to moderate pain and reduce fever. This action supports the patient in feeling more comfortable during recovery from various minor illnesses.

Typical indications for its use include: temporary relief of aches, minor pains, and fever associated with conditions like the common cold, the flu, headache, toothache, and menstrual cramps. The medication may be an accessible option for addressing general discomfort in these everyday clinical scenarios.

The application of the medication in these contexts is focused on the management of fever and pain symptoms during the recovery process.

Quick Fact: Supports the temporary relief of minor aches and fever

Eligibility and Restrictions for Use

Official Eligibility: Who Can and Cannot Use Anadol?

Anadol (Tramadol Hydrochloride) is an opioid analgesic whose use is strictly defined by regulatory authorities based on population safety and physiological status. Eligibility rules determine who may safely use the medicine and who must be formally excluded, a status known as contraindication.


Contraindicated Populations and Conditions

Population Group/Condition Status (Regulatory Mandate)
Children younger than 12 years of age Absolute Contraindication
Children younger than 18 years post-tonsillectomy/adenoidectomy Absolute Contraindication
Patients on Monoamine Oxidase Inhibitors (MAOIs) (or within 14 days) Absolute Contraindication
Patients with significant respiratory depression or uncontrolled epilepsy Contraindicated
Known or suspected gastrointestinal obstruction Contraindicated

Populations Requiring Conditional or Restricted Use

  • Organ Impairment: Patients with severe hepatic or renal impairment must use Anadol with caution, typically requiring dosage adjustments as officially directed.
  • Older Adults: Patients over 75 years of age may require a dose interval extension due to altered drug elimination.
  • Reproductive Status: Use during pregnancy is generally not recommended due to the risk of Neonatal Opioid Withdrawal Syndrome. Use while breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The active ingredient in Anadol (tramadol) is associated with several serious interactions due to its effects on both opioid receptors and the reuptake of norepinephrine and serotonin.

Do Not Combine:

  • Monoamine Oxidase (MAO) Inhibitors: The combination of tramadol with MAO inhibitors is contraindicated and must be avoided. This includes drugs like isocarboxazid, linezolid, and phenelzine, or within 14 days of their use, due to a heightened risk of potentially fatal serotonin syndrome or increased central nervous system (CNS) effects.

Combinations Requiring Caution or Dose Adjustment:

  • Central Nervous System (CNS) Depressants: Co-administration with other depressants—including alcohol, opioids, tranquilizers, sedatives, hypnotics, and general anesthetics—increases the risk of profound sedation, severe respiratory depression, coma, and death. If combination is necessary, a reduced dose of one or both agents and close monitoring is required.

  • Serotonergic Drugs: Using Anadol with other serotonergic agents (such as SSRIs, SNRIs, and Triptans) can increase the risk of serotonin syndrome.

  • Drugs that Affect Metabolism: Medicines that inhibit the liver enzymes CYP2D6 or CYP3A4 (e.g., quinidine, fluoxetine, ketoconazole) can increase tramadol concentration, raising the risk of seizures and other adverse effects. Conversely, inducers like carbamazepine increase the metabolism of tramadol, which may reduce its pain-relieving effect, potentially requiring an increased Anadol dose.

  • Drugs that Lower the Seizure Threshold: The risk of seizures is increased when Anadol is taken with medicines that also lower the seizure threshold, such as certain antidepressants and antipsychotics.

Mechanism of Action

How Anadol Works

Anadol (Tramadol) operates through a dual, synergistic mechanism that primarily engages the central nervous system (CNS) to modulate signal flow.

Central mu-Opioid Receptor Activation

This domain focuses on the M1 metabolite (O-desmethyl-tramadol), which is produced via CYP2D6 enzyme activity. The M1 metabolite functions as a high-affinity agonist at the mu-opioid receptors ( MORs) located in the spinal cord and brain. Activation of these receptors initiates a cellular cascade that dampens ascending signal transmission by limiting the release of specific neurochemicals. This mechanism alters the flow and intensity of signals transmitted through the CNS, which defines the physiological response.

Enhancement of Descending Inhibitory Pathways

This separate but complementary mechanism involves the parent drug, which acts as a weak inhibitor of the reuptake of the neurotransmitters norepinephrine and serotonin. By increasing the concentration of these mediators in the synaptic cleft, the drug functionally enhances the activity of descending pathways involved in the regulation of signal transmission at the spinal level. This action modulates the activity within the nociceptive system.

Mechanistic Role of Bioactivation

The full pharmacological effect is contingent upon the body's metabolic conversion of the parent compound into the M1 metabolite. This dependence on the CYP2D6 enzyme introduces an inherent biological variability, meaning the degree of mu-opioid receptor engagement is constrained by individual differences in enzyme activity.

Dosage and Administration Information

How Anadol is Used in Clinical Practice

Anadol (Tramadol Hydrochloride) is used according to specific dosage protocols and routes. The medication is available for oral use, including immediate-release (IR) and extended-release (ER) tablets or capsules, and as a solution for parenteral administration via the intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes.


Administration Routes and Dosing Patterns

The choice of formulation determines the frequency pattern of use:

  • Immediate-Release Forms: These are typically administered every 4 to 6 hours as needed, with a standard adult dose ranging from 50 mg to 100 mg. The total daily intake does not exceed 400 mg. This form may be taken with or without food.
  • Extended-Release Forms: These are used for around-the-clock management, starting typically at 100 mg and administered once daily. The dose is swallowed whole and is not cut, crushed, or chewed, as this alters the slow-release mechanism.
  • Injections: Solutions for injection are administered via IV, IM, or SC routes, often at 50 mg to 100 mg every 4 to 6 hours, primarily in a controlled clinical setting.

Population and Procedural Adjustments

Dosage adjustments are utilized for certain patient populations. For example, the maximum daily dose for immediate-release forms is generally limited to 300 mg for adults over 75 years of age. Additionally, the dosing interval is extended in cases of renal or hepatic impairment. When discontinuing the medication, the dose is tapered gradually during the process of cessation of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anadol

Evidence for Use in Acute Pain

Research examining Anadol's component was studied for pain related to acute pain primarily involves short-term randomized controlled trials (RCTs) and supporting meta-analyses. These studies monitored patient-reported outcomes describing perceived discomfort and track how symptom intensity changes over a defined time interval, usually in the immediate period following surgical procedures. Studies compared the measurements of outcomes related to physical discomfort against those seen in participants who received a placebo. What remains uncertain is the applicability of these findings to all types of acute pain, as most high-quality evidence focuses on the initial 24 to 48 hours following surgery.

Evidence for Chronic Pain Management

Research examining Anadol in conditions characterized by fluctuating or episodic manifestations has been explored through both individual RCTs and comprehensive Systematic Reviews and Meta-Analyses. These studies focused on outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort over several weeks or months.

Studies on Chronic Low Back Pain and Osteoarthritis Pain

Research examined Anadol in adult populations with chronic low back pain and osteoarthritis, monitoring change in pain intensity and functional measures. Data show patterns related to small, statistically measured changes in pain scores when compared to placebo. However, major scientific reviews indicate that this observed change in pain intensity may be below the difference considered meaningful in a daily-life setting. The evidence quality varies across studies, and research provides limited insight into long-term functional improvement.

Duration of Studies and Long-Term Follow-Up

The core evidence supporting the use of Anadol is derived from trials with limited follow-up durations, typically ranging up to around 16 weeks for chronic pain studies. This research provides insight into short-term changes, but there is limited information for long-term outcomes regarding the durability of its effect or the maintenance of observed changes over one year or more. Long-term effects are not fully established through high-quality controlled trials.

What is Still Uncertain About the Research for Anadol

Research describes that an individual’s genetic makeup may influence how the body processes the medicine; research describes observed patterns related to changes in outcomes. Limited information is available on whether Anadol is associated with sustained changes in metrics of daily life, such as physical function or quality of life, beyond the first few months of use. Research does not determine whether an individual will respond similarly to the group patterns observed in clinical trials, as the results apply only to the populations studied and genetic differences are known to affect outcomes.

Frequently Asked Questions (FAQ)

Common questions about Anadol (FAQ)


Q: Is Anadol a pain reliever or something else?

A: Anadol is officially classified as an opioid analgesic, a class of medicine used in the management of moderate to severe pain. It is a centrally acting synthetic opioid that works in the central nervous system.

Q: How quickly does Anadol start working?

A: According to official product information, the analgesic effect for the immediate-release forms of Anadol is typically observed within one hour after administration. This observation may vary depending on the individual and the formulation used.

Q: How long does the effect of Anadol typically last?

A: The duration of the analgesic activity for the immediate-release formulation is generally described in official sources as being approximately six hours. Extended-release formulations are designed to maintain effects for a longer duration.

Q: Is it okay to take Anadol every day?

A: Official guidelines for chronic pain management include regimens for around-the-clock dosing using extended-release forms, indicating daily use is a pattern described in official documents. Official documents recommend that the necessity and continuation of long-term treatment be monitored.

Q: What happens if I forget to take a dose of Anadol?

A: Official instructions usually describe how to handle a missed dose, often by taking it when remembered, unless it is close to the next scheduled dose. Instructions emphasize the importance of not taking two doses simultaneously to compensate for a missed dose.

Q: Is there a risk of withdrawal symptoms if Anadol is stopped suddenly?

A: Regulatory documents advise that Anadol can lead to physical dependence with chronic use. Official instructions state that to minimize the risk of withdrawal symptoms, a gradual reduction (tapering) of the dose is advised when the medication is discontinued.

Q: Can Anadol be used by people with kidney problems?

A: Regulatory documents state that for people with renal (kidney) impairment, the drug's elimination is delayed. Official instructions indicate that patients with severe renal impairment require an extended dose interval, and in the most severe cases, use may be contraindicated or not recommended.

Q: Is Anadol suitable for people with liver disease?

A: Official documents indicate that the elimination of Anadol is delayed in patients with hepatic (liver) insufficiency. Official instructions indicate that patients with severe hepatic insufficiency require an extended dose interval, and use may be contraindicated or not recommended. Usage is conditional upon the severity of the impairment described in the labeling.

Q: Can pregnant or breastfeeding women use Anadol?

A: Official regulatory documents classify use during pregnancy as generally not recommended due to a documented risk of Neonatal Opioid Withdrawal Syndrome in the infant. Use while breastfeeding is also not recommended as the drug is known to pass into breast milk.

Q: Do regulatory agencies classify Anadol as a controlled substance?

A: Yes. For example, in the United States, regulatory agencies classify Anadol as a Schedule IV controlled substance. Its legal status and specific scheduling can vary by country.

Q: Can I drive or operate machinery while taking Anadol?

A: The official labeling states that Anadol may impair mental and physical abilities, especially tasks requiring focus and coordination. Due to the potential for impairment, the drug may affect the ability to safely drive a car or operate machinery.

Q: Does taking Anadol affect blood pressure?

A: Official safety information includes hypotension (low blood pressure) as a potential, though often uncommon or rare, adverse reaction. This indicates that an effect on blood pressure is described in the official safety profile, particularly when initiating therapy or after a dose increase.

Q: Can Anadol cause changes in mood or anxiety?

A: Regulatory documents list central nervous system (CNS) effects such as confusion as a possible side effect. Rare instances of mood changes or psychiatric disorders have also been noted in official safety information.

Q: Is Anadol known to cause stomach upset?

A: Yes, official safety information lists Nausea and Vomiting as Very Common or Common side effects. These are recognized forms of gastrointestinal discomfort that can occur frequently when taking the medication.

Q: Are there certain foods or drinks that should be avoided with Anadol?

A: Regulatory sources explicitly state that alcohol should be avoided because it increases the risk of serious CNS depressant effects. Additionally, some official product information may recommend avoiding substances like grapefruit or grapefruit juice due to potential interaction with the drug's metabolism.

Q: Does Anadol interact with herbal remedies like St. John's Wort?

A: Official labeling advises caution with medicines that affect serotonin levels. As St. John's Wort can act as a serotonergic agent, its co-administration could potentially increase the risk of developing a high level of serotonin in the body.

Q: Are there specific vitamins or supplements that interact with Anadol?

A: Regulatory information indicates that common vitamins have generally not been found to have clinically significant interactions. However, official advice always recommends disclosing all supplements, including vitamins, to a health professional, as interactions remain possible.

Q: What kind of studies have been done on Anadol?

A: The core evidence for Anadol's use is referenced in regulatory documents and includes various studies. These typically consist of Randomized Controlled Trials (RCTs) and supporting papers such as Meta-Analyses or Systematic Reviews for its main therapeutic uses.

Q: Does Anadol need to be taken at a specific time of day?

A: Official dosing instructions specify administration based on either symptom need ('as needed') or regular time intervals (e.g., 'once daily' or 'every 4 to 6 hours'). There is no regulatory requirement for a fixed time like morning or evening, unless directed by a health professional.

How should Anadol be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for this medication are based on official government regulatory documents (e.g., EMA, FDA, MHRA).

Storage Category Official Requirement
Child Safety Keep out of the reach of children.
Container Integrity Store in the original package.
Temperature / Light Store in accordance with package instructions (typically room temperature).
Stability Shelf-life is typically 36 months when stored correctly.

Official Disposal Rules

When disposing of unused or expired medicine, official guidance prioritizes public and environmental safety:

  1. Drug Take-Back Programs: Utilize authorized drug take-back or mail-back programs, which are the preferred method for disposal.
  2. Household Trash: If a take-back program is unavailable, mix the medicine with an undesirable substance (such as used coffee grounds or dirt). Place this mixture in a sealed bag or container and dispose of it with the household trash.
  3. Privacy: Scratch out all personal information on the packaging before discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anadol found in:

A-Z Index: